Suchergebnisse - "olaparib"

PubPharm (2.279)

91

Personalized medicine for metastatic prostate cancer : The paradigm of PARP inhibitors

enthalten in: Critical reviews in oncology/hematology | 2023

von Maiorano, B. | Conteduca, V. | Catalano, M. | +4

92

PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis

enthalten in: Anticancer research | 2023

von Kim, C. | Kim, D. | Lee, D. | +3

93

Increase in serum creatinine levels after PARP inhibitor treatment

enthalten in: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology | 2023

von You, D. | Zhong, L. | Yin, R. | +1

94

Triggering pyroptosis enhances the antitumor efficacy of PARP inhibitors in prostate cancer

enthalten in: Cellular oncology (Dordrecht) | 2023

von Tian, A. | Wu, T. | Zhang, Y. | +3

95

Does Early Olaparib Administration Improve Prognosis in Patients with HER2-Negative Metastatic Breast Cancer and BRCA1 and/or BRCA2 Pathogenic Variants?-A Case Report

enthalten in: Gan to kagaku ryoho. Cancer & chemotherapy | 2023

von Takuwa, H. | Sasaki, S. | Yamada, T. | +1

96

Serum CA125 level as predictors of the efficacy of olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer

enthalten in: The journal of obstetrics and gynaecology research | 2023

von Asano, F. | Momomura, M. | Morisada, T. | +5

97

Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells

enthalten in: Scientific reports | 2023

von Biegała, �. | Gajek, A. | Szymczak-Pajor, I. | +3

98

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

enthalten in: Breast cancer research and treatment | 2023

von Balmaña, J. | Fasching, P. | Couch, F. | +22

99

Combination therapy with poly(adenosine diphosphate-ribose) polymerase (PARPi) and androgen receptor signaling pathway (ARPi) inhibitors for metastatic castration-resistant prostate cancer

enthalten in: Urologie (Heidelberg, Germany) | 2023

von Grimm, M. | Foller, S. | Leucht, K.

100

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38) : a phase IIIb trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Pujade-Lauraine, E. | Selle, F. | Scambia, G. | +21

CommentOn: Ann Oncol. 2023 Dec;34(12):1074-1076. - PMID 38072509